BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Batiha GE, Beshbishy AM, Alkazmi LM, Nadwa EH, Rashwan EK, Yokoyama N, Igarashi I. In vitro and in vivo growth inhibitory activities of cryptolepine hydrate against several Babesia species and Theileria equi. PLoS Negl Trop Dis 2020;14:e0008489. [PMID: 32853247 DOI: 10.1371/journal.pntd.0008489] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tudu CK, Bandyopadhyay A, Kumar M, Radha, Das T, Nandy S, Ghorai M, Gopalakrishnan AV, Proćków J, Dey A. Unravelling the pharmacological properties of cryptolepine and its derivatives: a mini-review insight. Naunyn Schmiedebergs Arch Pharmacol 2023;396:229-38. [PMID: 36251044 DOI: 10.1007/s00210-022-02302-7] [Reference Citation Analysis]
2 Bastos RG, Laughery JM, Ozubek S, Alzan HF, Taus NS, Ueti MW, Suarez CE. Identification of novel immune correlates of protection against acute bovine babesiosis by superinfecting cattle with in vitro culture attenuated and virulent Babesia bovis strains. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.1045608] [Reference Citation Analysis]
3 Ji S, Galon EM, Amer MM, Zafar I, Yanagawa M, Asada M, Zhou J, Liu M, Xuan X. Phosphatidylinositol 4-kinase is a viable target for the radical cure of Babesia microti infection in immunocompromised hosts. Front Cell Infect Microbiol 2022;12. [DOI: 10.3389/fcimb.2022.1048962] [Reference Citation Analysis]
4 Bastos RG, Alzan HF, Rathinasamy VA, Cooke BM, Dellagostin OA, Barletta RG, Suarez CE. Harnessing Mycobacterium bovis BCG Trained Immunity to Control Human and Bovine Babesiosis. Vaccines 2022;10:123. [DOI: 10.3390/vaccines10010123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Nandy A, Shekhar S, Paul BK, Mukherjee S. Exploring the Nucleobase-Specific Hydrophobic Interaction of Cryptolepine Hydrate with RNA and Its Subsequent Sequestration. Langmuir 2021;37:11176-87. [PMID: 34499515 DOI: 10.1021/acs.langmuir.1c02123] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hildebrandt A, Zintl A, Montero E, Hunfeld KP, Gray J. Human Babesiosis in Europe. Pathogens 2021;10:1165. [PMID: 34578196 DOI: 10.3390/pathogens10091165] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 8.5] [Reference Citation Analysis]
7 Renard I, Ben Mamoun C. Treatment of Human Babesiosis: Then and Now. Pathogens 2021;10. [PMID: 34578153 DOI: 10.3390/pathogens10091120] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
8 Adeola HA, Bano A, Vats R, Vashishtha A, Verma D, Kaushik D, Mittal V, Rahman MH, Najda A, Albadrani GM, Sayed AA, Farouk SM, Hassanein EHM, Akhtar MF, Saleem A, Abdel-Daim MM, Bhardwaj R. Bioactive compounds and their libraries: An insight into prospective phytotherapeutics approach for oral mucocutaneous cancers. Biomed Pharmacother 2021;141:111809. [PMID: 34144454 DOI: 10.1016/j.biopha.2021.111809] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
9 Zhang Y, Alvarez-Manzo H, Leone J, Schweig S, Zhang Y. Botanical Medicines Cryptolepis sanguinolenta, Artemisia annua, Scutellaria baicalensis, Polygonum cuspidatum, and Alchornea cordifolia Demonstrate Inhibitory Activity Against Babesia duncani. Front Cell Infect Microbiol 2021;11:624745. [PMID: 33763384 DOI: 10.3389/fcimb.2021.624745] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]